ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMSpese di vendita, generali e amministrative1.64 M2.46 M2.38 M1.75 M2.33 M1.69 M8.15 MRicerca e sviluppo4.48 M4.43 M4.01 M3.74 M3.7 M3.68 M15.13 MReddito operativo-6.12 M-6.89 M-6.39 M-5.49 M-6.03 M-5.37 M-23.29 MProventi non operativi, Totale185.48 K-9 5410-3 77160.94 K-12.85 K44.31 KOneri finanziari, al netto degli interessi capitalizzati—————88 K—Proventi non operativi, esclusi gli oneri finanziari00000-88 K-88 KEntrate/uscite straordinarie185.48 K-9 5410-3 77160.94 K-12.85 K44.31 KUtile al lordo delle imposte-5.93 M-6.9 M-6.39 M-5.49 M-5.97 M-5.38 M-23.24 MQuota di utile———————Imposte———————Interessi di minoranza———————Altri proventi/oneri al netto delle imposte135-1351 046——-2 301—Utile netto al lordo delle attività cessate-6.77 M-7.07 M-6.57 M-5.66 M-6.1 M-5.47 M-23.81 MAttività cessate———————Utile netto-6.77 M-7.07 M-6.57 M-5.66 M-6.1 M-5.47 M-23.81 MRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari-6.77 M-7.07 M-6.57 M-5.66 M-6.1 M-5.47 M-23.81 MUtile base per azione (EPS base)———————Utile diluito per azione (EPS diluito)-2.72-3.3-2.4-1.360.74-0.68-3.7Numero medio di azioni ordinarie in circolazione———————Azioni diluite in circolazione1.8 M2.18 M2.82 M4.15 M4.06 M8.02 M19.04 MEBITDA—-7.06 M-6.57 M-5.65 M-6.13 M-5.45 M-23.81 MEBIT—-7.06 M-6.57 M-5.66 M-6.16 M-5.46 M-23.85 MCosto del fatturato———————Altri costi del venduto———————Ammortamento e svalutazione (liquidità)32 K8 0007 0007 00027 K5 00046 K
Cel-Sci Corporation
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint.